Qiagen (QGEN) Stock Price, News & Analysis

Company Overview

Qiagen N.V. (NYSE: QGEN) is a global leader in sample and assay technologies for molecular diagnostics, applied testing, academic research and pharmaceutical development. Founded in 1984 and headquartered in Hilden, Germany, the company develops and supplies products that enable the extraction, purification, amplification and detection of DNA and RNA from complex biological samples. Qiagen’s solutions underpin a wide range of applications, including infectious disease testing, cancer diagnostics, genetic research and blood screening.

The company’s portfolio encompasses a variety of consumables, instruments and software. Sample preparation tools such as spin columns, automation platforms and flexible kits ensure reliable nucleic acid recovery. Qiagen’s amplification technologies include real-time PCR instruments, digital PCR systems and multiplex assays, supporting high-sensitivity detection of pathogens and genomic targets. In addition, the firm offers comprehensive bioinformatics tools that streamline data analysis, interpretation and workflow integration for both clinical and research laboratories.

Qiagen serves customers in over 35 countries, with major operations in Europe, North America, the Asia-Pacific region and Latin America. Its end markets include clinical laboratories, molecular diagnostics companies, pharmaceutical and biotechnology firms, academic institutions and government agencies. The company maintains a broad distribution network and collaborates with healthcare providers and research organizations to advance molecular testing capabilities and address emerging public health challenges.

Led by Chief Executive Officer Thierry Bernard, Qiagen places a strong emphasis on innovation, quality and customer support. The executive team focuses on expanding the company’s assay portfolio through strategic partnerships, acquisitions and internally driven research and development. By investing in new diagnostic platforms and digital solutions, Qiagen aims to enhance the speed, accuracy and accessibility of molecular testing, supporting both routine healthcare delivery and cutting-edge life science research.

Key Stats

• Today's Range: $47.77 to $48.82
• 50-Day Range: $41.23 to $48.07
• 52-Week Range: $37.63 to $49.30
• Volume: 1.01 million shs
• Average Volume: 1.19 million shs
• Market Capitalization: $10.71 billion
• P/E Ratio: 120.83
• Dividend Yield: N/A
• Price Target: $49.40
• Consensus Rating: Hold

Qiagen Stock Analysis - MarketRank™

Qiagen scored higher than 75% of companies evaluated by MarketBeat, and ranked 266th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Qiagen has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Qiagen has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 8.85%

Earnings Growth

Earnings for Qiagen are expected to grow by 8.85% in the coming year, from $2.26 to $2.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Qiagen is 120.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.87.

Price to Earnings Ratio vs. Sector

The P/E ratio of Qiagen is 120.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.35.

Price to Earnings Growth Ratio

Qiagen has a PEG Ratio of 2.44. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Qiagen has a P/B Ratio of 3.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.63% of the float of Qiagen has been sold short.

Short Interest Ratio / Days to Cover

Qiagen has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Qiagen has recently decreased by 11.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: N/A

Dividend Yield

Qiagen does not currently pay a dividend.

Dividend Growth

Qiagen does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Qiagen will have a dividend payout ratio of 10.16% next year. This indicates that Qiagen will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

2.63% of the float of Qiagen has been sold short.

Short Interest Ratio / Days to Cover

Qiagen has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Qiagen has recently decreased by 11.30%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.68

News Sentiment

Qiagen has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Qiagen this week, compared to 8 articles on an average week.

Search Interest

Only 1 people have searched for QGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Qiagen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.00% of the stock of Qiagen is held by insiders.

Percentage Held by Institutions

70.00% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

QGEN Stock Analysis - Frequently Asked Questions

How have QGEN shares performed this year?

Qiagen's stock was trading at $43.2931 at the start of the year. Since then, QGEN shares have increased by 11.3% and is now trading at $48.19.
View the best growth stocks for 2025 here.

How were Qiagen's earnings last quarter?

Qiagen N.V. (NYSE:QGEN) announced its earnings results on Wednesday, May, 7th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.05. Qiagen's revenue was up 5.2% compared to the same quarter last year.
Read the conference call transcript.

When did Qiagen's stock split?

Qiagen shares split before market open on Wednesday, January 29th 2025.The 36-35 split was announced on Wednesday, January 22nd 2025. The newly minted shares were distributed to shareholders after the market closes on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the split would have 103 shares after the split.

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Qiagen investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and PayPal (PYPL).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/01/2025
• Ex-Dividend for 7/10 Dividend: 7/02/2025
• Record date for 7/10 Dividend: 7/03/2025
• Dividend Payable: 7/10/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:QGEN
• CIK: 1015820
• Web: www.qiagen.com
• Phone: (177) 355-6600
• Fax: 31-77-355-6658
• Employees: 6,030
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $49.40
• High Stock Price Target: $55.00
• Low Stock Price Target: $43.00
• Potential Upside/Downside: +2.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.40
• Trailing P/E Ratio: 121.12
• Forward P/E Ratio: 21.37
• P/E Growth: 2.44
• Net Income: $83.59 million
• Net Margins: 4.68%
• Pretax Margin: 6.91%
• Return on Equity: 14.61%
• Return on Assets: 8.80%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 3.37
• Quick Ratio: 2.83

Sales & Book Value

• Annual Sales: $1.98 billion
• Price / Sales: 5.43
• Cash Flow: $3.24 per share
• Price / Cash Flow: 14.90
• Book Value: $16.05 per share
• Price / Book: 3.01

Miscellaneous

• Outstanding Shares: 222,290,000
• Free Float: 202,285,000
• Market Cap: $10.74 billion
• Optionable: Optionable
• Beta: 0.67